Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I

Open source

DOI: 10.1136/jitc-2021-003487
Published: 2022 May
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2021-003487,
  title = {Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?},
  author = {Guedan S and Luu M and Ammar D and Barbao P and Bonini C and Bousso P and Buchholz CJ and Casucci M and De Angelis B and Donnadieu E and Espie D and Greco B and Groen R and Huppa JB and Kantari-Mimoun C and Laugel B and Mantock M and Markman JL and Morris E and Quintarelli C and Rade M and Reiche K and Rodriguez-Garcia A and Rodriguez-Madoz JR and Ruggiero E and Themeli M and Hudecek M and Marchiq I},
  year = {2022},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2021-003487},
  url = {https://doi.org/10.1136/jitc-2021-003487}
}

RIS

TY  - JOUR
TI  - Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
AU  - Guedan S
AU  - Luu M
AU  - Ammar D
AU  - Barbao P
AU  - Bonini C
AU  - Bousso P
AU  - Buchholz CJ
AU  - Casucci M
AU  - De Angelis B
AU  - Donnadieu E
AU  - Espie D
AU  - Greco B
AU  - Groen R
AU  - Huppa JB
AU  - Kantari-Mimoun C
AU  - Laugel B
AU  - Mantock M
AU  - Markman JL
AU  - Morris E
AU  - Quintarelli C
AU  - Rade M
AU  - Reiche K
AU  - Rodriguez-Garcia A
AU  - Rodriguez-Madoz JR
AU  - Ruggiero E
AU  - Themeli M
AU  - Hudecek M
AU  - Marchiq I
PY  - 2022
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2021-003487
UR  - https://doi.org/10.1136/jitc-2021-003487
ER  -

APA

S, G., M, L., D, A., P, B., C, B., P, B., CJ, B., M, C., B, D. A., E, D., D, E., B, G., R, G., JB, H., C, K., B, L., M, M., JL, M., E, M., C, Q., M, R., K, R., A, R., JR, R., E, R., M, T., M, H., & I, M. (2022). Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2021-003487

Source records

pubmed · retrieved 2026-09-26T14:12:33.230Z